Epitranscriptomic regulation of HIF-1: bidirectional regulatory pathways

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F86652036%3A_____%2F25%3A00618501" target="_blank" >RIV/86652036:_____/25:00618501 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/67985823:_____/25:00618501 RIV/00216208:11310/25:10501989

Výsledek na webu

<a href="https://doi.org/10.1186/s10020-025-01149-x" target="_blank" >https://doi.org/10.1186/s10020-025-01149-x</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1186/s10020-025-01149-x" target="_blank" >10.1186/s10020-025-01149-x</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Epitranscriptomic regulation of HIF-1: bidirectional regulatory pathways

Popis výsledku v původním jazyce

Background Epitranscriptomics, the study of RNA modifications such as N6-methyladenosine (m(6)A ), provides a novel layer of gene expression regulation with implications for numerous biological processes, including cellular adaptation to hypoxia. Hypoxia-inducible factor-1 (HIF-1), a master regulator of the cellular response to low oxygen, plays a critical role in adaptive and pathological processes, including cancer, ischemic heart disease, and metabolic disorders. Recent discoveries accent the dynamic interplay between m(6)A modifications and HIF-1 signaling, revealing a complex bidirectional regulatory network. While the roles of other RNA modifications in HIF-1 regulation remain largely unexplored, emerging evidence suggests their potential significance. Main body This review examines the reciprocal regulation between HIF-1 and epitranscriptomic machinery, including m(6)A writers, readers, and erasers. HIF-1 modulates the expression of key m(6)A components, while its own mRNA is regulated by m(6)A modifications, positioning HIF-1 as both a regulator and a target in this system. This interaction enhances our understanding of cellular hypoxic responses and opens avenues for clinical applications in treating conditions like cancer and ischemic heart disease. Promising progress has been made in developing selective inhibitors targeting the m(6)A -HIF-1 regulatory axis. However, challenges such as off-target effects and the complexity of RNA modification dynamics remain significant barriers to clinical translation. Conclusion The intricate interplay between m(6)A and HIF-1 highlights the critical role of epitranscriptomics in hypoxia-driven processes. Further research into these regulatory networks could drive therapeutic innovation in cancer, ischemic heart disease, and other hypoxia-related conditions. Overcoming challenges in specificity and off-target effects will be essential for realizing the potential of these emerging therapies.

Název v anglickém jazyce

Epitranscriptomic regulation of HIF-1: bidirectional regulatory pathways

Popis výsledku anglicky

Background Epitranscriptomics, the study of RNA modifications such as N6-methyladenosine (m(6)A ), provides a novel layer of gene expression regulation with implications for numerous biological processes, including cellular adaptation to hypoxia. Hypoxia-inducible factor-1 (HIF-1), a master regulator of the cellular response to low oxygen, plays a critical role in adaptive and pathological processes, including cancer, ischemic heart disease, and metabolic disorders. Recent discoveries accent the dynamic interplay between m(6)A modifications and HIF-1 signaling, revealing a complex bidirectional regulatory network. While the roles of other RNA modifications in HIF-1 regulation remain largely unexplored, emerging evidence suggests their potential significance. Main body This review examines the reciprocal regulation between HIF-1 and epitranscriptomic machinery, including m(6)A writers, readers, and erasers. HIF-1 modulates the expression of key m(6)A components, while its own mRNA is regulated by m(6)A modifications, positioning HIF-1 as both a regulator and a target in this system. This interaction enhances our understanding of cellular hypoxic responses and opens avenues for clinical applications in treating conditions like cancer and ischemic heart disease. Promising progress has been made in developing selective inhibitors targeting the m(6)A -HIF-1 regulatory axis. However, challenges such as off-target effects and the complexity of RNA modification dynamics remain significant barriers to clinical translation. Conclusion The intricate interplay between m(6)A and HIF-1 highlights the critical role of epitranscriptomics in hypoxia-driven processes. Further research into these regulatory networks could drive therapeutic innovation in cancer, ischemic heart disease, and other hypoxia-related conditions. Overcoming challenges in specificity and off-target effects will be essential for realizing the potential of these emerging therapies.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Molecular Medicine

ISSN

1076-1551

e-ISSN

1528-3658

Svazek periodika

31

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

13

Strana od-do

105

Kód UT WoS článku

001447417800003

EID výsledku v databázi Scopus

2-s2.0-105000244892